FGFR1 amplification is a breast cancer treatment target and is associated with endocrine therapy resistance.

被引：0
|
作者：
Turner, N. C. [1 ]
Iorns, E. [1 ]
Smith, A. [1 ]
Lambros, M. B. [1 ]
Reis-Filho, J. S. [1 ]
Ashworth, A. [1 ]
机构：
[1] Inst Canc Res, London SW3 6JB, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 106卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S124 / S124
页数：1
相关论文
共 50 条
  • [1] FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
    Turner, Nicholas
    Pearson, Alex
    Sharpe, Rachel
    Lambros, Maryou
    Geyer, Felipe
    Lopez-Garcia, Maria A.
    Natrajan, Rachael
    Marchio, Caterina
    Iorns, Elizabeth
    Mackay, Alan
    Gillett, Cheryl
    Grigoriadis, Anita
    Tutt, Andrew
    Reis-Filho, Jorge S.
    Ashworth, Alan
    CANCER RESEARCH, 2010, 70 (05) : 2085 - 2094
  • [2] FGFR1 and EGFR Amplification in Breast Cancer
    Chen, Hui
    Singh, Rajesh
    Huo, Lei
    Lu, Xinyan
    Bousamra, Alex
    Abraham, Ronald
    Mehrotra, Meenakshi
    Mishra, Bal Mukund
    Virani, Shumaila
    Chowdhuri, Sinchita Roy
    Routbort, Mark
    Aldape, Ken
    Broaddus, Russell
    Sahin, Aysegul
    Patel, Keyur
    Luthra, Rajyalakshmi
    MODERN PATHOLOGY, 2015, 28 : 38A - 38A
  • [3] FGFR1 and EGFR Amplification in Breast Cancer
    Chen, Hui
    Singh, Rajesh
    Huo, Lei
    Lu, Xinyan
    Bousamra, Alex
    Abraham, Ronald
    Mehrotra, Meenakshi
    Mishra, Bal Mukund
    Virani, Shumaila
    Chowdhuri, Sinchita Roy
    Routbort, Mark
    Aldape, Ken
    Broaddus, Russell
    Sahin, Aysegul
    Patel, Keyur
    Luthra, Rajyalakshmi
    LABORATORY INVESTIGATION, 2015, 95 : 38A - 38A
  • [4] FGFR1 is associated with resistance to interaction with estrogen receptor (ER) a endocrine therapy in ER+/FGFR1-amplified breast cancer
    Formisano, Luigi
    Young, Christian D.
    Bhola, Neil
    Giltnane, Jennifer M.
    Estrada, Monica V.
    Arteaga, Carlos L.
    CANCER RESEARCH, 2015, 75
  • [5] Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
    Formisano, L.
    Young, C. D.
    Bhola, N. E.
    Bulen, B.
    Estrada, V. M.
    Wagle, N.
    Van Allen, E.
    Brewer, M. L. Red
    Jansen, V. M.
    Guerrero, A. L.
    Giltnane, J. M.
    Strcker, T.
    Arteaga, C. L.
    CANCER RESEARCH, 2016, 76
  • [6] Unravelling the role of FGFR1 in innate immune sensing and endocrine resistance in breast cancer
    Dhakal, Sushil
    Lien, Torbjorn Amundsen
    Norum, Jens Henrik
    Bergholtz, Helga
    Flatekval, Helene Midtun
    Sorlie, Therese
    CANCER RESEARCH, 2024, 84 (09)
  • [7] Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification
    Cheng, Fiona Tsui-Fen
    Fu Ou-Yang
    Lapke, Nina
    Tung, Kai-Che
    Chen, Yen-Kung
    Chou, Yuh-Yu
    Chen, Shu-Jen
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2017, 15 (12): : 1456 - 1459
  • [8] FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
    Mouron, Silvana
    Manso, Luis
    Caleiras, Eduardo
    Rodriguez-Peralto, Jose L.
    Rueda, Oscar M.
    Caldas, Carlos
    Colomer, Ramon
    Quintela-Fandino, Miguel
    Bueno, Maria J.
    BREAST CANCER RESEARCH, 2021, 23 (01)
  • [9] FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
    Silvana Mouron
    Luis Manso
    Eduardo Caleiras
    Jose L. Rodriguez-Peralto
    Oscar M. Rueda
    Carlos Caldas
    Ramon Colomer
    Miguel Quintela-Fandino
    Maria J. Bueno
    Breast Cancer Research, 23
  • [10] FGFR1 Amplification in Breast Cancers with Unfavorable Features
    Pfaltz, K.
    Schneider, S.
    Eppenberger-Castori, S.
    Tapia, C.
    LABORATORY INVESTIGATION, 2012, 92 : 58A - 59A
12345